日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

LDI, A Lipid Droplet Inhibitor, Disrupts Lipid Accumulation and Modulates Hepatic Lipid Profiles in Fatty Liver.

LDI（一种脂滴抑制剂）可破坏脂质积累并调节脂肪肝中的肝脏脂质谱。

期刊:Advanced Materials
影响因子:26.8
doi:10.1002/adma.202506373
Kim Seunghee, Kim Yeojin, Paudel Sanjita, Kang In Young, Kim Suyeon, Kim Jeesoo, Park Sunmi, Koo Seung-Hoi, Kim Hyun Sung, Jun Dae Won, Park Jinyoung, Lee Hyunbeom, Lee Joonseok
脂肪肝
发表日期：2026
文献求助 收藏

Normal-weight metabolic dysfunction-associated steatotic liver disease: reclassification, characteristics, and adverse liver outcomes across diverse populations

正常体重代谢功能障碍相关脂肪肝疾病：不同人群的重新分类、特征和不良肝脏结局

期刊:Clinical and Molecular Hepatology
影响因子:16.9
doi:10.3350/cmh.2025.0851
Song, Sherlot Juan; Yoon, Eileen Laureal; Wong, Vincent Wai-Sun; Jo, Ae Jeong; Wong, Grace Lai-Hung; Lai, Jimmy Che-To; Jun, Dae Won; Yip, Terry Cheuk-Fung
脂肪肝
代谢
发表日期：2026
文献求助 收藏

Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease

评估代谢功能障碍相关脂肪肝疾病的成本效益治疗反应阈值

期刊:Clinical and Molecular Hepatology
影响因子:16.9
doi:10.3350/cmh.2025.0796
Yoon, Eileen L; Cho, Jeong-Yeon; Park, Huiyul; Kim, Mimi; Park, Ji-Hyeon; Kim, Hye-Lin; Jun, Dae Won
脂肪肝
代谢
发表日期：2026
文献求助 收藏

The MASLD Journey in the General Population: Linkage-to-Care and Patient-Reported Uptake of Fibrosis Risk Assessment

普通人群中的MASLD诊疗历程：与医疗服务的衔接及患者报告的纤维化风险评估接受情况

期刊:Liver International
影响因子:5.2
doi:10.1111/liv.70658
Oh, Joo Hyun; Lee, Jun-Hyuk; Ahn, Sang Bong; Kwon, Eunjoo; Yoon, Eileen L; Lee, Hyo Young; Cho, Seon; Jun, Dae Won
发表日期：2026
文献求助 收藏

Correction to: Misclassification of Alcohol Use Disorder in MASLD and MetALD: Prevalence, Clinical Characteristics, and Outcomes

更正：MASLD 和 MetALD 中酒精使用障碍的误诊：患病率、临床特征和结果

期刊:Gut and Liver
影响因子:3.2
doi:10.5009/gnl250072.e
Lee, Jun-Hyuk; Ahn, Sung-Ho; Park, Jimin; Jeon, So Young; Yoon, Eileen L; Lee, Hye Sun; Jun, Dae Won
发表日期：2026
文献求助 收藏

Correspondence to letter to the editor on "Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis"

致编辑的信函，主题为“减肥手术可改善肥胖患者的代谢功能障碍相关性脂肪性肝炎：系统评价和荟萃分析”

期刊:Clinical and Molecular Hepatology
影响因子:16.9
doi:10.3350/cmh.2024.0818
Cho, Yuri; Jun, Dae Won
肥胖
代谢
肝炎
发表日期：2025
文献求助 收藏

Age serves as the silent architect of FIB-4's precision in unveiling advanced hepatic fibrosis in MASLD with T2DM: Correspondence to letter to the editor on "Diagnostic accuracy of the fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: a systematic review and meta-analysis"

年龄是 FIB-4 在揭示伴有 2 型糖尿病的非酒精性脂肪性肝病 (MASLD) 中晚期肝纤维化方面发挥精准作用的幕后推手：对“纤维化-4 指数诊断伴有 2 型糖尿病的非酒精性脂肪性肝病晚期肝纤维化的准确性：系统评价和荟萃分析”一文的读者来信

期刊:Clinical and Molecular Hepatology
影响因子:16.9
doi:10.3350/cmh.2024.1160
Han, Ji Won; Jun, Dae Won
糖尿病
脂肪肝
代谢
发表日期：2025
文献求助 收藏

Correspondence to editorial on "Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis"

致编辑的信函，主题为“普通人群中具有临床意义的肝纤维化的患病率：系统评价和荟萃分析”

期刊:Clinical and Molecular Hepatology
影响因子:16.9
doi:10.3350/cmh.2024.0777
Kim, Hee Yeon; Choi, Miyoung; Jun, Dae Won
发表日期：2025
文献求助 收藏

Correspondence to letter to the editor on "Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis"

致编辑的信函，主题为“普通人群中具有临床意义的肝纤维化的患病率：系统评价和荟萃分析”

期刊:Clinical and Molecular Hepatology
影响因子:16.9
doi:10.3350/cmh.2024.0937
Kim, Hee Yeon; Choi, Miyoung; Jun, Dae Won
发表日期：2025
文献求助 收藏

Solving care labor shortages through employee-driven experiments: A multiple case study

通过员工主导的实验解决护理人员短缺问题：一项多案例研究

期刊:Clinical and Molecular Hepatology
影响因子:16.9
doi:10.3350/cmh.2024.0163
Jin, Young-Joo; Kim, Hee Yeon; Suh, Young Ju; Lee, Chae Hyeon; Yu, Jung Hwan; Kim, Mi Na; Han, Ji Won; Lee, Han Ah; An, Jihyun; Chon, Young Eun; Jun, Dae Won; Choi, Miyoung; Kim, Seung Up; Weiste, E; Saari, E; Lappalainen, K; Koivisto, T
发表日期：2025
文献求助 收藏